Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Fig. 4

Latent class analysis of patient CDAI responses in D2T RA cases. A Three CDAI response trajectories obtained by latent analysis. Group 1, rapid responders; group 2, slow responders; and group 3, less-responders. B Percentages of patients included in each group by treatment subgroups. CDAI, Clinical Disease Activity Index; D2T RA, difficult-to-treat rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin; JAKi, Janus kinase inhibitor

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us